Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -0.76%86 Operating Margin % is 34.94% as of Mar. 2026, which is 81% above its 10-year median of 19.32. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,049.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 960 Drug Manufacturers companies, Procter & Gamble Health ranks better than 94.37% on this metric.
Procter & Gamble Health Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Procter & Gamble Health's Operating Margin % or its related term are showing as below:
BOM:500126'
s Operating Margin % Range Over the Past 10 Years
Min: 5.4 Med: 19.32 Max: 30.76
Current: 30.76
BOM:500126's Operating Margin % is ranked better than 94.37% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.58
vs BOM:500126: 30.76
Procter & Gamble Health (BOM:500126) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Procter & Gamble Health Operating Margin % Related Terms
Procter & Gamble Health Operating Margin % Historical Data
* Premium members only.
The historical data trend for Procter & Gamble Health's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500126 vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's Operating Margin % falls into.
Procter & Gamble Health Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Procter & Gamble Health's Operating Margin % for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health (BOM:500126) has a Operating Margin % of 34.94% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Procter & Gamble Health and its competitors. This is 81% above median its historical median of 19.32. Over the past decade, Procter & Gamble Health's Operating Margin % has ranged from 5.40 to 30.76. According to the industry distribution chart, Procter & Gamble Health ranks #54 out of 960 companies in the Drug Manufacturers industry, placing it in the top 5.6%.
Is Procter & Gamble Health's Operating Margin % too high?
Procter & Gamble Health's current Operating Margin % of 34.94% is 81% above median its 10-year median of 19.32. Over the past 10 years, this metric has ranged from a low of 5.40 to a high of 30.76. The Drug Manufacturers industry median Operating Margin % is 7.58. Procter & Gamble Health's value of 34.94% is 360.9% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #54 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #54 out of 960 companies for Operating Margin %. This places Procter & Gamble Health in the top 6% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.58. Procter & Gamble Health's value of 34.94% is 360.9% above this benchmark. Historically, Procter & Gamble Health's own Operating Margin % has ranged from 5.40 to 30.76 over the past decade. While the company's 10-year median is 19.32 vs. the industry median of 7.58, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current Operating Margin % of 34.94% is 360.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current Operating Margin % is 34.94%, which is 81% above median its own 10-year median of 19.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,049.27, compared to a current price of ₹6,797.90 — trading 12.4% above its estimated fair value. The current Operating Margin % is 34.94%, which is 81% above median its 10-year median of 19.32 and 360.9% above the Drug Manufacturers industry median of 7.58. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Operating Margin % is 34.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued.
The current stock price of ₹6,797.90 is trading 12.4% above its estimated GF Value™ of ₹6,049.27.
GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.
Key valuation signals for BOM:500126:
Operating Margin %: 34.94% (81% above median its 10-year median of 19.32)
GF Value™: ₹6,049.27 vs. price of ₹6,797.90 (12.4% above fair value)
Industry Position: 360.9% above the Drug Manufacturers median (#54 of 960)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score
Get the complete analysis for BOM:500126
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
